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ABSTRACT 
Prior clinical studies have demonstrated that a family history of coronary artery disease (CAD) is associated with 
future cardiovascular events. Although there are several Mendelian disorders that are associated with CAD, most 
common forms of CAD are believed to be multifactorial and the result of many genes with small individual 
effects. The identification of these genes and their variation would be very helpful for the prediction, prevention, 
and management of CAD; linkage analysis or candidate gene case-control studies have been largely unsuccessful. 
On the contrary, recent advances in genomic techniques have generated a large amount of deoxyribonucleic acid 
(DNA)-based information. The link between CAD and inflammation and biological pathways has been highlight-
ed. In particular, several genome-wide association studies have replicated a novel gene marker on chromosome 
9p21. The information gained from genomic studies, in combination with clinical data, is expected to refine per-
sonalized approaches to assess risk and guide management for CAD. Genetic risk scores derived from several 
functional single nucleotide polymorphisms (SNPs) or haplotypes in multiple genes may improve the prediction 
of CAD. Despite the complexity of CAD genetics, steady progress is expected. (Korean Circ J 2009;39:129-137) 
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Introduction 
 
Atherosclerotic coronary artery disease (CAD) is a 
major health problem worldwide. Intensive studies have 
been reported and are currently ongoing for appropriate 
risk assessment, prevention, and treatment of CAD. A 
small proportion of CAD cases may be attributed to rare, 
monogenic effects with high penetrance, but most CAD 
cases are multifactorial in etiology. Development of CAD 
is only roughly defined by traditional cardiovascular risk 
factors. In the Framingham Heart Study, a parental his-
tory of premature vascular disease was a strong risk fac-
tor (adjusted odds ratio=1.7-2.0).
1) The INTERHEART 
study confirmed that a family history of CAD is an im-
portant risk factor (adjusted odds ratio=1.5).
2) However, 
because the Framingham risk scoring, which is the most 
widely used risk assessment tool, does not include fam-
ily history, thus refining a CAD prediction model is 
needed. At the same time, with the advances in genomic 
research, the potential for translating genomic informa-
tion to clinical practice is greater now than ever before. 
During the last 50 years, we have witnessed a remark-
able progression of genomic studies, from the initial 
description of the deoxyribonucleic acid (DNA) double 
helix by Watson and Crick in 1953 to the completion of 
the Human Genome Project in 2003. Indeed, genomics 
is now being used to identify newly discovered pathogens 
in an effort to stratify patients according to the risk of a 
disease by genotyping, and to assess the effects and guide 
therapy. Technological breakthroughs in genetics and 
genomics have facilitated an understanding of disease 
pathogenesis.
3) The Human Genome Project and Inter-
national HapMap Project have provided a large amount 
of DNA-based information. In addition, current tech-
nology can assess the expression of thousands of genes 
from different tissues. 
The term, personalized medicine, indicates disease 
prevention and treatment based on knowledge of indi-
vidual genetic susceptibilities. By combining informa-
tion gained through genomic methodologies with tradi-
tional methodologies, we expect to advance our ability to 
assess and treat CAD better. In particular, because DNA-
based genetic markers remain unchanged throughout 
one’s life, genetic tests for disease prediction could be 
performed at a young age to promote early intervention. 
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This review considers basic concepts and approaches, 
recent genomic studies on CAD, and the clinical impli-
cations for personalized medicine.   
 
Basic Concepts and Approaches 
in Genomic Research 
 
The 20,000-25,000 protein coding genes that com-
prise the human genome represent only 30% of its se-
quence. The remainder is intergenic sequences that may 
contain elements for the regulation of gene expression. 
In a typical human gene, 5% of the sequence is coding 
exons that are partly translated into a protein, and the 
remainder is composed of introns and regulatory regions. 
The most common human sequence variations are dif-
ferences in individual base pairs, termed single nucleo-
tide polymorphisms (SNPs). Other variations consist of 
short or long repetitions of the same motif, such as 
mini- and micro-satellites, insertion or deletions, and 
variants that affect large chromosomal regions.   
 
Mendelian versus complex inheritance 
Genetic variation predisposing to CAD spans from 
rare and highly deleterious mutations related to Men-
delian disease to common polymorphisms with weak ef-
fects, that alone or in combination, are associated with 
the risk of common diseases (common variants-weak ef-
fect-common disease model).
4) Rare deleterious muta-
tions (e.g., mutations that cause familial hypercholes-
terolemia) are related to an important risk for CAD; 
however, the impact at the population level is low. In 
contrast, frequent polymorphisms, such as the apolipo-
protein E polymorphism, may have a population impact 
despite the weak effect at the individual level. Because 
polymorphisms have common alleles, numerous combi-
nations of susceptibility alleles at several loci in an in-
dividual are possible. Furthermore, some of the combi-
nations of susceptibility alleles can affect the risk for 
CAD in a way that cannot be predicted from the separate 
effect of each variant. Since this is the major problem 
when one characterizes the genetics of complex traits, it 
is rational and justified to explore systems of genes rather 
than a single gene. 
Almost all polymorphisms identified by association 
studies have a modest effect, even when combined. Fur-
thermore, there is a marked disparity between the extent 
of familial aggregation and those collectively accounted 
for by known variants in common diseases. One emerg-
ing hypothesis suggests that a significant proportion of 
this unknown area of heritability can be explained by 
low-frequency intermediate penetrance variants. To date, 
however, these variants have been unyielding to conven-
tional gene-seeking approaches (Fig. 1).
5) 
 
Genetic linkage and candidate gene association 
studies 
Two basic approaches have been used to discover ge-
netic influence on diseases:6) genetic linkage and candi-
date gene association studies. Genetic linkage studies use 
genetic and phenotypic data from families. Linkage an-
alysis intends to localize genomic regions that might con-
tain genes influencing a trait. On the contrary, candidate 
gene association studies compare genotypic frequencies 
between cases and control groups. A statistical difference 
in frequencies between the groups suggests that a gen-
otype is associated with the trait. Genetic association 
studies rely on the existence of linkage disequilibrium 
(LD) among polymorphic sites which are physically close 
within the genome. It is referred to as LD when two 
alleles at different loci occur together on the same chro-
mosome more often than would be predicted. Even if a 
causal involvement of a polymorphism in the disease is 
not proven, the association may be suggested by a meas-
ured proxy polymorphism in LD. Because of LD iden-
tified in most regions of the genome, the combination 
of alleles at neighboring SNPs (haplotypes) generates 
less diversity than would be expected. By re-sequencing 
the genome of 270 individuals from populations from 
African, Asian, and European ancestries, the HapMap 
Project has demonstrated a set of SNPs that tag most 
common haplotypes in humans. This resource can be 
used to search for polymorphisms associated with sus-
ceptibility to common diseases. Recent technological ad-
vances have allowed relatively low-cost dense genotyping 
arrays of 500,000 or more SNPs that cover most of the 
genome. For complex diseases, by typing hundreds of 
thousands of variants, genome-wide association studies 
provide excellent power. Specifically, genome-wide asso-
ciation studies are expected to help to resolve the ques-
tions regarding contribution of multiple variants to com-
mon diseases.   
 
Genetic Susceptibility  
to Coronary Artery Disease 
 
Until recently, most studies on the genetics of CAD 
Fig. 1. Variants with different frequencies, penetrance, and dis-
ease susceptibility. GWA: genome-wide association. 
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were based on candidate genes. Accordingly, reports of 
genetic variations in CAD came from established risk 
factors, such as hyperlipoproteinemia, hypertension, and 
thrombosis. Nevertheless, relatively few polymorphisms 
in candidate genes were replicated for CAD.   
 
Rare mutations causing premature coronary artery 
disease  
Disease-causing mutations are defined as rare allelic 
variants that can markedly increase disease risk. Molec-
ular genetic studies of rare, Mendelian forms of CAD 
have identified several mutations that cause premature 
CAD (Table 1). Many of the mutations affect the levels 
of low density lipoprotein (LDL) and high density lipo-
protein (HDL)-cholesterol. Mutations in the LDL re-
ceptor gene (LDLR), which is associated with the ma-
jority of patients with familial hypercholesterolemia, is a 
classic example. Gain-of-function and loss-of-function 
variants of the proprotein convertase subtilisin/kexin 9 
(PCSK9) gene, which modulates LDL receptor levels, has 
been reported to be associated with a reduction of LDL 
and CAD.
7) Both variants are inherited in an autosomal 
dominant fashion with increased plasma LDL-chole-
sterol. Tangier disease is characterized by the absence of 
HDL-cholesterol and low plasma apoA-1. This disease 
results from mutations in the ATP-binding cassette 
transporter type 1 (ABCA1) gene and is associated with 
premature myocardial infarction.   
 
Genetic linkage studies 
Before the recent introduction of high-density SNP 
genotyping arrays, linkage analysis, also called positional 
cloning, using families with multiple affected individuals 
was considered the most useful way to identify suscep-
tibility loci. Very few genes have been identified from 
genetic linkage studies, and the lack of replication em-
phasizes the difficulties in performing and interpreting 
these studies. The identification of the arachidonate 5-
lipoxygenase-activating protein (ALOX5AP) gene encod-
ing 5’-lipoxygenase activating protein (FLAP) represents 
one success in detecting a novel candidate from a linkage 
study.
8) A few genome-wide linkage studies conducted 
for subclinical forms of atherosclerotic vascular disease 
have exhibited linkage evidence on chromosomes 10
9) 
and 12.
10) Among the observed linkage regions on chro-
mosomes 1, 2, 3, 13, 14, 16, 17, and X, only the linkage 
region detected by the PROCARDIS consortium on 
chromosome 17 was clearly replicated.
11) It can be inferr-
ed from genome-wide linkage studies that there are no 
CAD loci with strong effects. In the future, putative loci 
that are implicated from genome-wide linkage scans are 
likely to help select regions for large-scale association 
studies.  
 
Candidate gene association studies 
Candidate gene studies have attempted to investigate 
variations in genes that are already implicated in the 
pathophysiology of disease. A large number of candidate 
gene association studies have been performed for myo-
cardial infarction and atherosclerotic vascular disease, 
but few studies have been replicated. In addition, because 
risk ratios have largely been modest in association stud-
ies, meta-analyses often have been necessary to obtain 
statistical significance (Table 2). These analyses were 
shown in a large number of studies evaluating variants 
of the apolipoprotein E (APOE),
19) plasminogen activator 
inhibitor 1 (PAI1),
22) angiotensin-1 converting enzyme 
Table 2. Candidate gene variation for atherothrombotic cardiovas-
cular disease reported in recent meta-analyses of association 
studies 
Gene  Risk allele  Risk ratio  References 
MTHFR  C677T 1.1-1.2 12 
CETP  TaqlB 0.8  13 
PON1  Q192R 1.1-1.2 14 
eNOS  T-786C 1.3  15 
Prothrombin  G20210A 1.2  16 
APOB  Ins/Del (DD)  1.3  17 
Glycoprotein IIIa  Pl(A2) 1.1  18 
APOE  ε4/ε4 1.4  19 
ACE insertion/deletion  DD 1.2  20 
APOB  Splns/Del (DD), 
Ecorl (AA) 
1.2-1.7 21 
PAI1  4G/5G 1.2  22 
Fibrinogen β-chain  G-455A 0.7  22 
MTHFR: methylene tetrahydrofolate reductase, CETP: cholesteryl
ester transfer protein, eNOS: endothelial nitric oxide synthase, AP-
OE: apolipoprotein E, ACE: angiotensin converting enzyme, PAI1:
plasminogen activator inhibitor   
 
 
Table 1. Rare Mendelian diseases that cause premature CAD
Disease  Gene  Phenotypic changes  Percentage of premature MI (%) 
Familial hypercholesterolemia    LDLR  Increased LDL due to defective binding of LDL by receptor  5 
Hypercholesterolemia type 3  PCSK9  Increased LDL due to degradation of LDLR    5 
Familial defective APOB  APOB  Increased VLDL-cholesterol and LDL-C  
due to decreased affinity of APOB to LDLR 
2 
Familial combined hyperlipidemia  Unknown  Increased LDL and triglyceride      2 
Tangier  disease     ABCA1  Impaired cholesterol efflux in Macrophages (foam cells)  Rare 
CAD: coronary artery disease, LDLR: low-density lipoprotein receptor, PCSK9: proprotein convertase subtilisin/kexin type 9, APO: apoli-
poprotein, LDL-C: LDL-cholesterol, ABCA 1: adenosine triphosphate (ATP)-binding cassette transporter type 1 
  
 
132·Personalized Medicine in CAD 
 
(ACE),
20) and methylene tetrahydrofolate reductase (M-
THFR) genes.
12) Recently, high-throughput genotyping 
has been used in case-control studies. Variations in lym-
photoxin-alpha (LTA),
23) gap junction protein, a-4 (GJA4 
or connexin 37),
24) matrix metalloproteinase-3 (MMP3 or 
stromelysin-1),
24) arachidonate 5-lipolygenase (ALOX5) 
genes,
24) and thrombospondin (THBS) genes
25) are asso-
ciated with myocardial infarction (MI). Among many 
studies on subclinical atherosclerosis, the 5A/6A poly-
morphism of the matrix metalloproteinase (MMP3) 
gene
26) revealed a consistent association with carotid in-
tima-media thickness. Two candidate gene association 
studies have provided evidence for a role of the leuko-
triene pathway in CAD susceptibility. Promoter variants 
in the ALOX5AP gene are associated with increased ca-
rotid intima-media thickness.
27) Another component of 
the leukotriene pathway which is considered a candidate 
gene for CAD is the leukotrine A4 hydrolase (LTA4H) 
gene. A recent study has shown an association between 
LTA4H and CAD and confirmed the importance of 
genetic variation in an inflammatory pathway gene in 
the development of CAD.   
 
Genome-wide association studies and the 9p21   
locus 
Genome-wide association studies that use large num-
bers of tagging SNPs have now come to replace linkage 
studies. In 2007, the first generation of genome-wide 
association studies using high-density, SNP genotyping 
arrays demonstrated several genetic variants that are sig-
nificantly associated with CAD (Table 3).
28-31) The design 
of these studies was quite simple. The frequencies of a 
large number of SNPs genotyped on arrays were com-
pared between cases and controls, and the sites that 
showed significant differences were then validated in in-
dependent samples. There was no prior assumption of 
candidate genes, rather the search for associated genes 
throughout the genome was unbiased.
32) 
Currently, the most robust susceptibility locus for 
CAD is on chromosome 9p21.
28-31) The association of 
this locus and CAD has been confirmed in independent 
Caucasian populations comprising greater than 55,000 
individuals. In all of these studies, 9p21 was confined to 
a 58,000 bp region and the coronary risk was indepen-
dent of traditional risk factors. As there is no known 
gene coding for a protein in the 58,000-bp region, the 
neighboring cyclin-dependent kinase inhibitor 2A (CD-
KN2A), cyclin-dependent kinase inhibitor 2B (CDNK2B), 
and methylthioadenosine pohosphorylase (MTAP) genes 
were initially suggested as candidates. The PROCARDIS 
consortium conducted an analysis of this CAD/type 2 
diabetes susceptibility locus on chromosome 9 and dem-
onstrated co-location of a high-risk haplotype with AN-
RIL, a large antisense non-coding RNA gene.
33) It was 
shown to be expressed in tissues and cells affected by 
atherosclerosis. ANRIL has now been identified as the 
most probable candidate gene for the 9p21 locus. The 
9p21 58,000 bp region is a target of major research and 
the mechanism whereby 9p21 causes CAD may imply a 
new pathway for cardiovascular risk independent of tra-
ditional risk factors. 
 
Focusing on genes in biological pathways   
in coronary artery disease 
A useful approach to search for candidate gene variants 
for CAD is to identify biological pathways in the de-
velopment of CAD. Four interdependent pathways have 
been described:34) lipoprotein handling, endothelial in-
tegrity, arterial inflammation, and thrombosis (Fig. 2). 
First, as familial hypercholesterolemia is related to a 
LDL receptor deficiency, abnormal lipoprotein handling 
is known to promote atherosclerosis. In addition, pro-
tective and at-risk alleles of APOE correlate with the 
effects on LDL-cholesterol.
19) PCSK9 loss-of-function 
mutations can reduce the LDL level and remarkably 
limit the development of CAD.
7) Regarding HDL-cho-
lesterol, rare variants of multiple genes are associated 
with low HDL levels. Specifically, non-synonymous var-
iants in three genes (ABCA1, APOA1, and LCAT) were 
associated with the population variance of a low HDL. 
A series of human studies have shown how a genetic var-
iation of apolipoprotein A-V (APOA5), in combination 
with apolipoprotein C-III (APOC3), influences triglyce-
ride levels. Several recent studies support the link be-
tween the APOA1-APOC3-APOA4-APOA5 cluster and 
familial combined hyperlipidemia through a mechanism 
Table 3. Susceptibility loci identified in four genome-wide asso-
ciation studies of CAD 
Number of subjects 
(cases/controls) 
SNPs on 
array 
Chromosome  
locus/SNP 
References 
322/312 100,000  9p21/rs10757274  28 
   9p21/rs2383206   
1607/6728 300,000  9p21/rs10757278 29 
   9p21/rs2383207   
1988/3004 500,000  9p21/rs1333049  30 
   1q43/rs17672135   
   5q21/rs383830   
   6q25/rs6922269  
   16q23/rs8055236   
   19q12/rs7250581   
   22q12/rs688034   
875/1644 500,000  2136.3/rs2943634  31 
   6q25.1/rs6922269   
   9p21.3/rs1333049   
   1p13.3/rs599839   
   1q41/rs17465673   
   10q11.21/rs501120   
   15q22.33/rs17228212   
CAD: coronary artery disease, SNP: single nucleotide polymorphism  
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that involves alleles in the APOA5 and APOC3 loci.
35) 
Another positional candidate gene, USF1  (upstream 
transcription factor 1), has shown evidence of an as-
sociation with several familial combined hyperlipidemia 
phenotypes. This gene encodes a transcription factor that 
is implicated in the regulation of several apolipoproteins 
and other proteins.
36) Secondly, endothelial integrity is 
an important factor that contributes to the pathophys-
iology of CAD. The thrombospondin family of extracel-
lular matrix proteins, which affects endothelial cell ad-
hesion and proliferation, was identified to be possibly 
associated with premature MIs
25) and the association 
has been confirmed by a subsequent study.
24) Connexin 
37 is a gap junction protein; the C1019T gene variant 
has been identified to have an association with MIs. 
Wang et al.
37) identified a variation in the myocyte en-
hancer factor 2a (MEF2A) gene in a family with MIs; 
the association with MIs has been confirmed by a subse-
quent study. Third, the arterial inflammation process 
has been implicated in several studies. LTA, lectin galac-
toside-binding soluble 2 (LGALS2),
23) the leukotriene 
pathway involving ALOX5AP and LTA4,
8) and the his-
tocompatibility factor (MHC2TA) promoter, A168G 
SNP,
38) are known to be related to inflammatory dis-
eases, such as rheumatoid arthritis, multiple sclerosis, 
and MIs. Fourth, thrombosis has been implicated in 
CAD in previous studies. In a comprehensive meta-an-
alysis, the 1691A variant of factor V (FV) and the 20210A 
variant of prothrombin were shown to be associated with 
CAD. The platelet glycoprotein receptor variants, vesicle-
associated membrane protein 8 (VAMP-8) and PAI-1, 
have also been implicated as risk factors for CAD.
39) 
 
Studies performed recently in the Korean   
population 
During the last decade in Korea, there has been re-
markable progress in the field of genomic research. Many 
genomic studies on CAD were candidate gene associa-
tion studies.   
Several studies involving SNPs with CAD risk factors 
have been published. Park et al.
40) showed a relationship 
between a cholesteryl ester transfer protein (CETP) Taq1B 
polymorphism and HDL-cholesterol levels and CAD. 
I405V, another CETP polymorphism, was reported to 
have a protective effect against CAD.
41) The R219K var-
iant of the ABCA1 gene was associated with high plasma 
HDL-cholesterol levels and a reduced severity of CAD.
42) 
The  APOA5 gene -1131T>C polymorphism has been 
reported to affect triglyceride levels, lipoproteins, and 
oxidative stress.
43) A polymorphism of the adiponectin 
gene (AdipoQ), G276T, is associated with metabolic pa-
rameters that contribute to CAD.
44) The risk for CAD 
based on specific folate levels required by the different 
MTHFR C677T genotype has been demonstrated.
45) Re-
cently, the association of the ADD1 G460W polymor-
phism and the risk of CAD was observed.
46) 
Evidence on the association between genes regulating 
inflammatory processes and CAD is accumulating. As-
sociations between polymorphisms of endothelial nitric 
oxide synthase (eNOS),
47-49) the NADH/NADPH oxidase 
Fig. 2. Biological pathways implicated in CAD pathophysiology and examples of genes. PCSK9: proprotein convertase subtilisin/kexin 9, 
APOA5: apoliprotein A-V, USF1: upstream transcription factor 1, CAD: coronary artery disease, FLAP: 5’-lipoxygenase activating protein, 
OX40L: OX40 ligand, MEF2A: monocyte enhancer factor 2a, GP: glycoprotein, LDL: low-density lipoprotein-cholesterol, HDL: high-
density lipoprotein-cholesterol, TG: triglyceride, EC: endothelial cell. 
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p22phox gene,
48) the C-1562T polymorphism of gela-
tinase B promoter, and CAD exist.
50) The oxidative stress-
related paraoxonase gene Q192R polymorphism is a risk 
factor for coronary spasm and stenosis.
51) A variant of 
the lipoprotein-associated phospholipase A2 (Lp-PLA2) 
gene
52) and several polymorphisms of chemokine re-
ceptor 2 (CCR2) have also been reported to be associated 
with CAD.
53) An association of polymorphisms with the 
receptor for advanced glycation end products (RAGE) 
gene and CAD have been shown.
54) On the other hand, 
regulated upon activation, normally T cell-expressed and 
presumably secreted (RANTES) -403G>A promoter pol-
ymorphism have been shown to be related to a reduced 
risk for CAD.
55) Reports on genes related to thrombosis 
or MIs include: G-33A polymorphism in the thrombo-
modulin (TM) gene,
56) human platelet antigen-3 (HPA-
3),
57) prostacyclin synthase C1117A,
58) prothrombin (PT) 
T165M,  FV R485K polymorphism,
59) and pregnancy-
associated plasma protein-A (PAPP-A) IVS6+95C allele.
60) 
In recent case-control studies, investigators expanded the 
association of 9p21 SNPs with CAD in Koreans beyond 
Caucasian populations.
61) 
 
Integration of data from genomic, molecular, and 
clinical medicine for the prediction of coronary artery 
disease 
Recent successes in the identification of susceptibility 
variants have increased confidence that this information 
can be translated into clinical management. More and 
more genes and gene products are considered important 
in assessing patients at risk for CAD. Although single 
genetic polymorphisms increase individual risk, the in-
tegration of information from several polymorphisms 
can become clinically useful.
62) 
Markers of inflammation or plaque vulnerability may 
become part of clinical practice. However, most of the 
markers that have been discussed have not been vali-
dated in large-scale clinical studies. Thus, risk stratifica-
tion and clinical decision-making may have the form of 
a combination of analysis of candidate genes, and mul-
tiple molecular and clinical factors. In addition, infor-
mation regarding genomics and phenotypic markers 
must be considered in the context of an individual’s 
medical history and environmental variables (Fig. 3). 
 
Pharmacogenomics  
in Cardiovascular Diseases 
 
The clinical goal of pharmacogenomics is to deliver 
the right drug to the right patient by accurate prediction 
of a therapeutic response and safety before prescription. 
In prior studies, commonly used cardiovascular medi-
cations, such as lipid-lowering agents, antihypertensives, 
and warfarin, have shown different effects on the basis 
of individual variation.   
Associations between lipid response to HMG-CoA 
reductase inhibitors and variation in the HMG-CoA 
reductase gene have been found.
63) In hypertension, var-
iation in the alpha-adducin (ADD1) gene was associated 
with renal sodium reabsorption and salt-sensitive hy-
pertension. Thus, variation in this gene might identify 
who would benefit more from diuretic therapy. Polymor-
phisms of the ACE pathway also show the possibility of 
clinical application of pharmacogenomics. Patients with 
the ACE DD genotype, which is associated with death 
or the need for transplantation in chronic heart failure, 
have shown the greatest benefit from beta-blocker or 
high-dose ACE inhibitor therapy. Variation in drug me-
tabolism is related to implication for pharmacogenomics. 
Genetic variants of the enzyme that metabolizes warfa-
rin, cytochrome P-450 2C9 (CYP2C9), and of a phar-
macologic target of warfarin, vitamin K epoxide reductase 
(VKORC1), have been demonstrated to contribute to 
differences in patients’ reponses to warfarin treatment.
64) 
Fig. 3. Combining information from genomic, molecular, and clinical data for personalized medicine in coronary artery disease.
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Conclusions 
  
In recent years, DNA sequence information, sophisti-
cated genetic methods, and advances in statistics and 
bioinformatics have allowed researchers to identify some 
variation in genes that modify the risk for CAD. In par-
ticular, the consistently replicated locus on 9p21 related 
to non-coding RNA gene represents a region of high 
priority for further investigation.   
Several limitations of current genomic approaches also 
need to be reviewed. First, before a personalized medicine 
for CAD becomes a reality, researchers need to validate 
novel markers in large independent cohorts, usually 
achieved by collaborative efforts. Second, unlike condi-
tions such as age-related macular degeneration or dia-
betes, CAD has a wide range of clinical manifestations. 
Consequently, CAD cohorts usually have genotypic he-
terogeneity. Moreover, the lack of a clear definition for 
control subjects is also a significant problem. Third, al-
though genomic study is to benefit an individual pa-
tient, because of the small effect size of most genetic risk 
factors, it may make only modest influence. Therefore, 
genetic information can be useful when it identifies can-
didates for intervention and guides more effective use of 
interventions. 
In the coming years, we expect that the combination 
of genomic, clinical, and environmental risks will refine 
personalized approaches to treat potential CAD patients. 
Because DNA-based genetic markers remain static thr-
oughout life, predictive genetic tests could be performed 
at a young age to facilitate early intervention in high-
risk individuals. Genetic tests will add to rather than re-
place the clinical risk stratification.   
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